- Tango Therapeutics stock experienced a significant daily gain of 57.22%, reaching a new 52-week high, driven by breakthrough clinical trial results.
- Early-stage clinical data for its advanced pancreatic cancer treatment, combining vopimetostat with Revolution Medicines’ daraxonrasib, showed an impressive 92% objective response rate and a 90% progression-free survival rate at six months.
- Mizuho Securities analyst Joseph Catanzaro raised the price target for Tango Therapeutics to $36.00, signaling strong confidence in the company’s future performance and the drug’s potential.
Tango Therapeutics (NASDAQ:TNGX) is an innovative biotechnology company dedicated to developing novel cancer treatments. With a substantial market capitalization of approximately $3.69 billion, the company is capturing significant investor attention. This heightened interest follows an analyst from Mizuho Securities raising the price target for Tango Therapeutics, underscoring confidence in its future growth trajectory and market potential.
The Tango Therapeutics stock recently experienced a substantial daily gain of 57.22%, closing at a price of $31.79. This impressive surge established a new 52-week high for the Tango Therapeutics stock, which has a 52-week low of $3.12. The heightened investor interest is primarily driven by promising clinical trial results from one of its key programs.
As highlighted by Reuters, Tango Therapeutics announced strong early-stage clinical trial results for its advanced pancreatic cancer treatment. The trial combines its investigational drug, vopimetostat, with Revolution Medicines’ daraxonrasib. The combination therapy demonstrated an impressive 92% objective response rate (ORR), a critical metric that measures the percentage of patients whose tumors shrink or disappear after treatment.
Furthermore, the data revealed a 90% progression-free survival (PFS) rate at the six-month mark. This indicates that for 90% of patients, the cancer did not worsen for at least six months, suggesting a durable and meaningful clinical benefit for patients. Following these encouraging results, the company plans to advance this promising treatment into pivotal late-stage testing.
This positive clinical data prompted Joseph Catanzaro of Mizuho Securities to raise the price target for Tango Therapeutics to $36.00. When the target was set, the stock’s price was $31.08. This updated price target represents a potential upside of 15.83% for the stock, reflecting strong optimism about the drug’s therapeutic potential and market impact.
